<i>RASA1</i>/<i>NF1</i>-Mutant Lung Cancer: Racing to the Clinic?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 29343556.
- Also identified by DOI 10.1158/1078-0432.CCR-17-3597 and PMC identifier 5856629.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Although mutation of <i>NF1</i> has been described in non-small cell lung cancer (NSCLC), co-mutation with <i>RASA1</i>, another Ras-GTPase activating protein (RasGAP), defines a novel genetically defined subclass of NSCLC. <i>RASA1</i>/<i>NF1</i>-mutant cell lines are highly sensitive to MEK inhibitors, warranting clinical evaluation of MAPK inhibition in this subclass of patients. <i>Clin Cancer Res; 24(6); 1243-5. ©2018 AACR</i><i>See related article by Hayashi et al., p. 1436</i>.
Medical subject headings
- Carcinoma, Non-Small-Cell Lung
- Lung Neoplasms